Funding for this research was provided by:
Received: 7 December 2022
Accepted: 5 July 2023
First Online: 21 July 2023
: J-BA has acted as a consultant for Pierre Fabre Medicament. The remaining authors declare that they have no competing interests.
: This research was conducted according to the principles of the Declaration of Helsinki and local and international laws. As this was a retrospective study no regulatory approval or written informed consent was required. A declaration of compliance with reference methodology MR-004 (which governs the processing of personal data in the context of research not involving human subjects) was sent to the Commission Nationale de l’Informatique et des Libertés (CNIL), and all data were processed in accordance with this methodology. In accordance with the regulations applicable to the processing of personal data and European Regulation 2016/679 of 27 April 2016, BIOCODEX was the sole controller of the processing of the data collected during this research. A written note informing the patients of the use of their data was sent by post or given at a regular consultation. This note included the purpose of the research and the data to be collected, as well as the patient’s right to refuse the use of their medical data, without any consequences for their usual care. The methods for the patient to express opposition were also described. In the event of a death of the patient involved in the research, the investigator ensured that the patient had not objected in writing to the use of their personal data during their lifetime. If the patient had objected in writing, their data were not included in the research.
: Not applicable.